Goldman Sachs
NUVB icon

Goldman Sachs’s Nuvation Bio NUVB Stock Holding History

Goldman Sachs’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.28M Buy
1,929,953
+233,940
+14% +$1.3M ﹤0.01% 3221
2025
Q4 		$15.2M Buy
1,696,013
+493,397
+41% +$3.06M ﹤0.01% 2651
2025
Q3 		$4.45M Sell
1,202,616
-275,428
-19% -$751K ﹤0.01% 3752
2025
Q2 		$2.88M Buy
1,478,044
+453,421
+44% +$944K ﹤0.01% 3893
2025
Q1 		$1.8M Sell
1,024,623
-1,005,151
-50% -$2.29M ﹤0.01% 4239
2024
Q4 		$5.4M Buy
2,029,774
+705,604
+53% +$1.82M ﹤0.01% 3377
2024
Q3 		$3.03M Buy
1,324,170
+184,664
+16% +$563K ﹤0.01% 3775
2024
Q2 		$3.33M Sell
1,139,506
-320
-0% -$976 ﹤0.01% 3527
2024
Q1 		$4.15M Buy
1,139,826
+345,718
+44% +$664K ﹤0.01% 3275
2023
Q4 		$1.2M Buy
794,108
+381,555
+92% +$491K ﹤0.01% 4277
2023
Q3 		$553K Sell
412,553
-88,944
-18% -$148K ﹤0.01% 4613
2023
Q2 		$903K Buy
501,497
+103,356
+26% +$176K ﹤0.01% 4411
2023
Q1 		$661K Buy
398,141
+156,991
+65% +$318K ﹤0.01% 4667
2022
Q4 		$463K Sell
241,150
-303,197
-56% -$613K ﹤0.01% 4908
2022
Q3 		$1.22M Buy
544,347
+399,301
+275% +$1.14M ﹤0.01% 4374
2022
Q2 		$470K Sell
145,046
-571,399
-80% -$2.49M ﹤0.01% 5121
2022
Q1 		$3.77M Buy
716,445
+569,597
+388% +$3.2M ﹤0.01% 3622
2021
Q4 		$1.25M Buy
146,848
+92,075
+168% +$846K ﹤0.01% 4650
2021
Q3 		$545K Sell
54,773
-106,556
-66% -$966K ﹤0.01% 5142
2021
Q2 		$1.5M Sell
161,329
-58,964
-27% -$672K ﹤0.01% 4451
2021
Q1 		$2.3M Buy
220,293
+210,293
+2,103% +$2.35M ﹤0.01% 3858
2020
Q4 		$117K Buy
+10,000
New +$104K ﹤0.01% 5266

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs's NUVB Position: Q1 2026 in Review

Goldman Sachs increased its Nuvation Bio (NUVB) stake by 14% in Q1 2026, buying an estimated $1.3M and bringing the position to 1,929,953 shares worth $8.28M. The position accounts for ﹤0.01% of the portfolio, ranked #3221.

Goldman Sachs first reported a position in NUVB in Q4 2020 and has held it in 22 quarters since. The position peaked at $15.2M in Q4 2025. 231 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

  • Goldman Sachs held 1,929,953 shares of Nuvation Bio worth $8.28M as of Q1 2026.
  • Goldman Sachs bought 233,940 Nuvation Bio shares in Q1 2026, an estimated $1.3M.
  • Nuvation Bio made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3221 holding.
  • Goldman Sachs first reported a position in Nuvation Bio in Q4 2020 and has held it in 22 quarters since.
  • Goldman Sachs's Nuvation Bio position peaked at $15.2M in Q4 2025.
  • 231 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.